LEO Pharma

October 14, 2019

EADV 2019 – Pfizer carves out a niche for abrocitinib

One of the company’s Xeljanz follow-ons is slowly emerging from stealth mode in atopic dermatitis.

January 09, 2019

As takeover hopes build, 2018 provides a low bar to beat

Takeda gave biopharma’s M&A bill a big boost in 2018 but to see just how slow the year was, take a look at deal volumes.

August 06, 2018

Almirall spots an opportunity

The Spanish group shows again that there is a future in dermatology, but its Allergan deal really depends on the fate of one asset.

September 14, 2017

Therapy focus – Atopic dermatitis competition Jaks up

August 09, 2017

Dermira grabs big pharma castoff

May 22, 2017

Astrazeneca's dealing cannot mask its problems

August 24, 2016

Committed seller could give Pfizer an antibiotic bargain

November 16, 2015

Interview – Reality sets in for Almirall

November 12, 2015

Leo gets more skin in the dermatology game

May 07, 2014

Development-stage M&A premiums reward very patient investors

February 20, 2014

Mid-cap consolidation spree looks set to yield bigger deals

Load More